Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - beclometasone dipropionate; formoterol fumarate dihydrate - inhalation powder - 100microgram/1dose ; 6microgram/1dose

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - inhalation powder - 6microgram/1dose ; 200microgram/1dose

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - fluticasone (fluticasone furoate), vilanterol - powder for inhalation - 100mcg/dose+ 25mcg/dose

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - fluticasone (fluticasone furoate), vilanterol - powder for inhalation - 200mcg/dose+ 25mcg/dose

Singapūras - anglų - HSA (Health Sciences Authority)

orient europharma pte ltd - beclometasone dipropionate anhydrous (micronized); formoterol fumarate dihydrate (micronized) - powder, metered - beclometasone dipropionate anhydrous (micronized) 100mcg/dose; formoterol fumarate dihydrate (micronized) 6mcg/dose

Airija - anglų - HPRA (Health Products Regulatory Authority)

chiesi farmaceutici s.p.a. - beclometasone dipropionate; formoterol fumarate dihydrate - inhalation powder - 200 micrograms/ 12 microgram(s) - formoterol and beclometasone

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

siegfried barbera s.l. - indacaterol (indacaterol acetate), mometasone fuorat - inhalation powder, capsules hard - 150mcg+ 320mcg

Europos Sąjunga - anglų - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

Europos Sąjunga - anglų - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - vylaer spiromax is indicated in adults 18 years of age and older only.asthmavylaer spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.